Hemab Therapeutics

Investment area

Seed Investments



Date of investment

January 2023

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.

Visit site


Jørgen Søberg Petersen

Senior Partner

Department: Seed Investments

After 9 years in clinical and academic medicine in Denmark and in the United States, Jørgen spent 18 years in R&D Executive positions in Denmark, Switzerland, United States, France and Germany. Jørgen co-founded and built the Nasdaq-listed biotech company Zealand Pharma (ZEAL.CO), held senior leadership at Lundbeck and Novo Nordisk, and as SVP at Merck he established the Immunology franchise. He has industrial R&D experience across multiple therapeutic areas, including CNS, cardiovascular disease, diabetes, oncology and autoimmune disease, and has been involved in a number of major pharmaceutical licensing deals and alliances. Jørgen serves on the board of Acesion Pharma, Engimmune Therapeutics, Breye Therapeutics, Hemab Therapeutics, and Tribune Therapeutics.

Jørgen holds MD, PhD, and DMSc degrees from the University of Copenhagen and an MBA degree from the Technical University of Denmark.